Oxybutynin Chloride Tablet, Extended Release
Product Images NDC 72789-414

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Oxybutynin Chloride (NDC 72789-414). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Pd-rx Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

72789414 Label (72789414)

72789414 Label (72789414)
Label for Oxybutynin Chloride Extended Release 10 mg tablets by PD-Rx Pharmaceuticals, Inc. The label indicates oral administration, with 90 tablets per bottle. It includes safety warnings such as drowsiness and advisories against alcohol consumption. The label shows NDC 72789-414-90, lot number F24B52, and an expiration date of 01/2027.*
FDA Label Image

Figure 1 (Fig 1)

Figure 1 (Fig 1)
A line graph comparing mean plasma R-Oxybutynin concentrations (ng/mL) over 24 hours for oxybutynin chloride extended-release tablets 10 mg once daily (QD) versus oxybutynin 5 mg three times daily (TID). Concentration is plotted on the vertical axis and time in hours on the horizontal axis, with standard deviation error bars shown for each time point.*
FDA Label Image

Figure 2 (Fig 2)

Figure 2 (Fig 2)
A line graph showing mean R-Oxybutynin plasma concentration (ng/mL) over time (hours). Concentration values fluctuate between approximately 0.5 and 0.7 ng/mL from 0 to 12 hours, with error bars indicating variability. Concentration returns near 0.5 ng/mL by 24 hours. The graph illustrates pharmacokinetic plasma levels over a 24-hour period.*
FDA Label Image

Figure 3 (Figure 3)

Figure 3 (Figure 3)
A horizontal bar chart comparing "Oxybutynin chloride extended-release tablets" and "Placebo." The chart displays data points for each treatment showing numerical values along the horizontal axis ranging from -40 to 40. The data points for oxybutynin chloride extended-release tablets indicate a negative value near -20, while the placebo group centers near zero.*
FDA Label Image

Figure 4 (Figure 4)

Figure 4 (Figure 4)
A chart comparing the effects or properties of Oxybutynin Chloride Extended Release Tablets and Oxybutynin. The chart spans values from -40 to 40 on the horizontal axis, showing relative positions and error bars for each product.*
FDA Label Image

Figure 5 (Figure 5)

Figure 5 (Figure 5)
A chart showing comparison data for oxybutynin chloride extended-release tablets and oxybutynin. The horizontal axis appears to range from -40 to 40, with points and error bars indicating measurement values and variability for each formulation.*
FDA Label Image

Structure (Structural Formula)

Structure (Structural Formula)
Chemical structure diagram of Oxybutynin Chloride showing the molecular connectivity with labeled atomic groups including a benzene ring, ester, alkyne, and quaternary ammonium components along with the chloride ion (HCl).*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.